<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Atypical (dysplastic) nevi
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Atypical (dysplastic) nevi
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Atypical (dysplastic) nevi
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allan Halpern, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth Quigley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hensin Tsao, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H14454900">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical nevi, also known as dysplastic nevi, are benign acquired melanocytic neoplasms characterized by irregular borders, variegated colors, and a diameter usually larger than 5 mm  (
         <a class="graphic graphic_picture graphicRef83351" href="/z/d/graphic/83351.html" rel="external">
          picture 1A
         </a>
         ). Although atypical nevi are benign lesions, they are strong phenotypic markers of an increased risk of melanoma, especially in individuals with numerous nevi and/or a family history of melanoma. Infrequently, atypical nevi may develop into melanoma [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will discuss the clinical features, diagnosis, and management of atypical nevi. Congenital nevi and common acquired melanocytic nevi are discussed separately. The clinical features and diagnosis of melanoma are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">
          "Congenital melanocytic nevi"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">
          "Acquired melanocytic nevi (moles)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1007470">
         <span class="h1">
          TERMINOLOGY AND HISTORICAL BACKGROUND
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1992, the National Institutes of Health in the United States issued a consensus statement recommending that the term "dysplastic nevus" be replaced with "atypical nevus" and that, histologically, lesions be diagnosed as "nevi with architectural disorder with a statement as to the presence and degree of melanocytic atypia" [
         <a href="#rid2">
          2
         </a>
         ]. In addition, the panel recommended that the syndrome for melanoma-prone families be referred to as "familial atypical mole melanoma (FAMM) syndrome."
        </p>
        <p>
         However, the terms "atypical nevi" and "dysplastic nevi" continue to be clinically used interchangeably, although a "dysplastic nevus" refers to a histologic diagnosis [
         <a href="#rid3">
          3,4
         </a>
         ]. Likewise, the term "familial atypical multiple mole melanoma (FAMMM) syndrome" continues to be in use.
        </p>
        <p>
         Terms that were previously used include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "B-K mole," "B-K mole syndrome," and "familial atypical multiple mole melanoma (FAMMM) syndrome" were first used in 1978 to describe a cutaneous phenotype characterized by multiple large, atypical moles associated with a family history of melanoma in two or more first-degree relatives [
         <a href="#rid5">
          5-7
         </a>
         ]. The terms "B-K mole" and "B-K mole syndrome" are no longer in common use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The term "dysplastic nevus syndrome" was introduced at the same time to describe individuals with sporadic (nonfamilial) melanoma who had any number of large, clinically and histologically atypical nevi [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The term "atypical mole syndrome" was subsequently applied to patients with many nevi (&gt;100), including some larger than 8 mm and with atypical features  (
         <a class="graphic graphic_table graphicRef86179" href="/z/d/graphic/86179.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14454921">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of any atypical nevi in White populations ranges from 2 to 10 percent [
         <a href="#rid11">
          11-14
         </a>
         ]. In a population-based, German study that included nearly 355,000 participants, the prevalence of clinically atypical nevi was 11.2 percent [
         <a href="#rid15">
          15
         </a>
         ]. Some of the prevalence variation is explained by differences in the diagnostic criteria used. In patients with a personal history of melanoma, the estimated prevalence is approximately 30 to 60 percent [
         <a href="#rid12">
          12,16,17
         </a>
         ]. There are no data on the prevalence of atypical nevi in skin of color populations.
        </p>
        <p>
         The prevalence of the familial atypical mole melanoma (FAMM) syndrome in the general population is unknown. (See
         <a class="local">
          'FAMM syndrome'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14454935">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development and density of nevi appear to be predominantly under genetic control, with ultraviolet light exposure playing an important modifying role [
         <a href="#rid18">
          18-21
         </a>
         ]. Data suggest that activating mutations of the oncogene
         <em>
          BRAF
         </em>
         V600E are sufficient for common nevogenesis [
         <a href="#rid22">
          22-26
         </a>
         ]. Data also suggest that syndromic atypical nevi arise de novo rather than from a pre-existing common nevus and have multiple driver mutations, including mutations known to activate mitogen-activated protein kinases (MAPKs) signaling, telomerase reverse transcriptase (
         <em>
          TERT
         </em>
         ) promoter mutations, or hemizygous alterations of
         <em>
          CDKN2A
         </em>
         [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Sporadic atypical nevi acquire somatic mutations, show a higher overall mutation burden than common nevi, and have
         <em>
          NRAS
         </em>
         or
         <em>
          BRAF
         </em>
         non-V600E mutations [
         <a href="#rid26">
          26,27
         </a>
         ]. Exome sequencing reveals that atypical nevi harbor a substantially lower mutational load than melanoma and differing ultraviolet signature mutation patterns, with cytosine to thymine transitions (eg, TC&gt;TT) more frequently found in melanoma than in atypical nevi [
         <a href="#rid27">
          27
         </a>
         ]. Recurrent
         <em>
          TERT
         </em>
         promoter mutations have been found in a significant proportion of atypical nevi [
         <a href="#rid28">
          28
         </a>
         ]. Germline mutations of the melanoma susceptibility genes (
         <em>
          CDKN2A
         </em>
         ,
         <em>
          ARF
         </em>
         ,
         <em>
          CDK4
         </em>
         ,
         <em>
          PTEN
         </em>
         ,
         <em>
          BRAF
         </em>
         ) have not been found in individuals with sporadic atypical mole syndrome [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H237810">
         <span class="h2">
          FAMM syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical nevi can occur sporadically or in a familial setting. The familial atypical mole melanoma (FAMM) syndrome, also called familial atypical multiple mole melanoma (FAMMM) syndrome, is an autosomal dominant condition characterized by a high number of common and atypical nevi (&gt;50) and history of melanoma in one or more first- or second-degree relatives [
         <a href="#rid30">
          30
         </a>
         ]. This syndrome is associated with pathogenic variants in the
         <em>
          CDKN2A
         </em>
         gene with reduced penetrance and variable expressivity. In a study of 385 families with three or more patients with melanoma from the Melanoma Genetics Consortium (GenoMEL), 39 percent of families had
         <em>
          CDKN2A
         </em>
         variants, ranging from 20 percent (32 of 162) in Australia, 45 percent (29 of 65) in North America, and 57 percent (89 of 157) in Europe [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         The
         <em>
          CDKN2A
         </em>
         gene is located on chromosome 9p21.3 and encodes the proteins p14ARF and p16(INK4), which are involved in the regulation of critical cell cycle pathways [
         <a href="#rid30">
          30
         </a>
         ]. Patients harboring the specific
         <em>
          CDKN2A
         </em>
         variants have an increased risk of early or multiple melanomas and other primary cancers, particularly pancreatic cancer [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4093872865">
         <span class="h1">
          HISTOLOGIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most, but not all, clinically atypical nevi manifest histologic dysplasia, which includes architectural disorder, cytologic atypia, and host response features (eg, lymphocytic, dermal infiltration; concentric, eosinophilic fibrosis; lamellar fibroplasia; and neovascularization) [
         <a href="#rid11">
          11,34
         </a>
         ].
        </p>
        <p>
         It should be noted that there is a continuum in the features that distinguish an atypical nevus from an in situ melanoma, and the line of demarcation between these diagnoses can be uncertain. Even among experienced pathologists, there is poor intra- and interobserver agreement in the diagnosis of melanocytic neoplasms ranging from moderately dysplastic lesions to melanoma in situ and T1a invasive melanoma [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Architectural disorder
         </strong>
         – Architectural disorder is defined by the combination of the following findings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lentiginous, melanocytic hyperplasia with elongation of rete ridges and proliferation of single or nested melanocytes in the basal layer
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral extension of the junctional component beyond the dermal component (shoulder phenomenon)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nests of melanocytes distributed at the sides of rete or at the suprapapillary dermoepidermal junction
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bridging or fusion of intraepidermal, melanocytic nests across adjacent retia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytologic atypia
         </strong>
         – Cytologic atypia is defined as the presence of a variable proportion of atypical melanocytes and is graded as mild, moderate, or severe. Atypical melanocytes are larger than normal and have large, hyperchromatic nuclei; irregular nuclear shape and nuclear polymorphism; abnormal chromatin pattern; and prominent nucleoli.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no universally accepted criteria for the diagnosis or grading of cytologic atypia. Several interobserver agreement studies found a good level of agreement among pathologists on the diagnosis of atypical nevi versus melanoma or benign melanocytic nevi but only a fair agreement in grading cytologic atypia [
         <a href="#rid35">
          35-39
         </a>
         ]. The 2018 World Health Organization (WHO) classification of skin tumors recommends using only two grades of dysplasia [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low grade
         </strong>
         – Nuclear size 1 to 1.5 times the nuclear size of resting basal cells, hyperchromasia or dispersed chromatin, prominent nuclear size in a small minority of cells (random atypia), small or absent nucleoli
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High grade
         </strong>
         – Nuclear size ≥1.5 times the nuclear size of resting basal cells; hyperchromasia, coarse granular chromatin, or peripheral condensation; prominent nuclear size in a larger minority of cells; prominent nucleoli
        </p>
        <p>
        </p>
        <p>
         The importance of the atypia grade in the assessment of melanoma risk for individual patients is uncertain. An observational study found a higher risk of melanoma in patients who had nevi with high-grade histologic atypia [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1008077">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H853000264">
         <span class="h2">
          Age of onset and natural history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical nevi usually first appear during puberty and may develop throughout life. In contrast, acquired common nevi appear after the age of six months, reach a peak count in the third decade, and then slowly regress with age. Atypical nevi arising on the scalp, breasts, or buttocks during childhood may be an early sign of high total body nevus count in adulthood [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
         Atypical nevi are dynamic in their clinical appearance. In a prospective study of 593 atypical nevi in 153 patients, 50 percent of nevi changed over an average of 89 months of follow-up, with 15 percent showing more atypical features [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H141858707">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical nevi are most often seen on the trunk and extremities, although they can develop anywhere on the body, including the scalp, breasts, buttocks, and genitalia  (
         <a class="graphic graphic_picture graphicRef78891 graphicRef53622" href="/z/d/graphic/78891.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. They rarely develop on the chronically sun-exposed skin of the face or hands [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Features that characterize a nevus as clinically atypical include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diameter in one dimension &gt;5 mm  (
         <a class="graphic graphic_picture graphicRef80725" href="/z/d/graphic/80725.html" rel="external">
          picture 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prominent macular component, sometimes with a papular center ("fried egg" or "target" appearance)  (
         <a class="graphic graphic_picture graphicRef83466" href="/z/d/graphic/83466.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mammillated (cobblestone) topography  (
         <a class="graphic graphic_picture graphicRef80725" href="/z/d/graphic/80725.html" rel="external">
          picture 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymmetry (one-half of the lesion does not match the other in terms of shape or color).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Notched, irregular, or ill-defined borders fading into surrounding skin  (
         <a class="graphic graphic_picture graphicRef70320" href="/z/d/graphic/70320.html" rel="external">
          picture 1C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variegated color, with areas of pink, tan, brown, or dark brown  (
         <a class="graphic graphic_picture graphicRef83351" href="/z/d/graphic/83351.html" rel="external">
          picture 1A
         </a>
         ). Other colors (eg, blue, red, or white) are not usually seen in atypical nevi, and their presence increases the probability that the lesion is a melanoma.
        </p>
        <p>
        </p>
        <p>
         It should be noted that, while these features may also be warning signs for melanoma, atypical nevi are considered benign neoplasms. Progression to melanoma can rarely occur and most often manifests as a new focal area of darker pigmentation or firm elevation  (
         <a class="graphic graphic_picture graphicRef83545 graphicRef83546" href="/z/d/graphic/83545.html" rel="external">
          picture 4A-B
         </a>
         ) [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Are atypical nevi melanoma precursors?'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H960751">
         <span class="h2">
          The 'signature nevus' and the 'ugly duckling' sign
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with multiple nevi, the predominant group of nevi that share similar clinical and dermoscopic features defines the "signature nevus" [
         <a href="#rid47">
          47,48
         </a>
         ]. The identification of nevi that appear different from the signature nevi, called "ugly ducklings" or "outliers," has been suggested as a screening method for the detection of melanoma in patients with many nevi, including those with many atypical nevi [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37327243">
         <span class="h2">
          Dermoscopic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         On dermoscopic examination, many atypical nevi fall into 1 of 10 benign dermoscopic patterns  (
         <a class="graphic graphic_figure graphicRef61160" href="/z/d/graphic/61160.html" rel="external">
          figure 1
         </a>
         ). These patterns, identified by examining large series of histologically confirmed atypical nevi, are based upon structural features and pigment distribution [
         <a href="#rid51">
          51,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions", section on 'Other algorithms and methods'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions", section on 'Dermoscopy from a management perspective'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16551.html" rel="external">
          "Dermoscopy of pigmented lesions of the palms and soles", section on 'Acquired melanocytic nevi'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticular diffuse  (
         <a class="graphic graphic_picture graphicRef54776" href="/z/d/graphic/54776.html" rel="external">
          picture 5
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticular patchy  (
         <a class="graphic graphic_picture graphicRef62442" href="/z/d/graphic/62442.html" rel="external">
          picture 6
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticular with central hypopigmentation  (
         <a class="graphic graphic_picture graphicRef78278" href="/z/d/graphic/78278.html" rel="external">
          picture 7
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticular with central hyperpigmentation  (
         <a class="graphic graphic_picture graphicRef57412" href="/z/d/graphic/57412.html" rel="external">
          picture 8
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homogeneous  (
         <a class="graphic graphic_picture graphicRef69190" href="/z/d/graphic/69190.html" rel="external">
          picture 9
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral reticular with central globules  (
         <a class="graphic graphic_picture graphicRef80161" href="/z/d/graphic/80161.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral globular  (
         <a class="graphic graphic_picture graphicRef55874" href="/z/d/graphic/55874.html" rel="external">
          picture 11
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Globular  (
         <a class="graphic graphic_picture graphicRef67691" href="/z/d/graphic/67691.html" rel="external">
          picture 12
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two-component pattern  (
         <a class="graphic graphic_picture graphicRef78854" href="/z/d/graphic/78854.html" rel="external">
          picture 13
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multicomponent pattern  (
         <a class="graphic graphic_picture graphicRef58486" href="/z/d/graphic/58486.html" rel="external">
          picture 14
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Atypical nevi that have eccentric peripheral hyperpigmentation or a multicomponent pattern are the most challenging to distinguish from melanoma. For this type of lesion, short-term digital dermoscopic monitoring or biopsy and histologic examination are necessary to exclude melanoma. (See
         <a class="local">
          'Dermoscopic examination and short-term dermoscopic monitoring'
         </a>
         below and
         <a class="local">
          'Excisional/complete biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2062132800">
         <span class="h1">
          CLINICAL SIGNIFICANCE
         </span>
        </p>
        <p class="headingAnchor" id="H1264179063">
         <span class="h2">
          Atypical nevi and melanoma risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical significance of atypical nevi lies in their association with an increased risk of melanoma [
         <a href="#rid12">
          12,53-58
         </a>
         ]. Individuals with atypical nevi have a 3- to 20-fold higher risk of developing a melanoma than individuals without atypical nevi [
         <a href="#rid55">
          55,59-61
         </a>
         ].
        </p>
        <p>
         The risk of melanoma increases in a dose-response fashion with the number of clinically atypical nevi and is greatest in individuals with atypical nevi and a personal or family history of melanoma [
         <a href="#rid17">
          17,55,59
         </a>
         ]. In a meta-analysis of observational studies, the relative risk of melanoma associated with atypical nevi was 1.5 (95% CI 1.3-1.6) for the presence of a single atypical nevus and 6.36 (95% CI 3.80-10.33) for five atypical nevi versus none [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H997619755">
         <span class="h2">
          Are atypical nevi melanoma precursors?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sporadic dysplastic nevi have been shown to be genetically intermediate between common nevi and melanoma, consistent with the clinical and histopathologic impression  (
         <a class="graphic graphic_table graphicRef129801" href="/z/d/graphic/129801.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid28">
          28,62
         </a>
         ]. Driver mutations in
         <em>
          BRAF
         </em>
         occur in common nevi as well as in dysplastic nevi and melanomas, with the mutation burden increasing from benign through intermediate lesions to melanoma, with a strong ultraviolet mutation signature. Intermediate lesions also have
         <em>
          TERT
         </em>
         promoter mutations in addition to the initiating
         <em>
          BRAF
         </em>
         mutation, while biallelic inactivation of
         <em>
          CDKN2A
         </em>
         marks the transition to invasive melanoma [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         However, the concept of the dysplastic nevus as a precursor necessary for the development of melanoma has never been proved. The risk of an individual atypical nevus progressing to melanoma is very small, and most of them will never develop a melanoma. Nonetheless, progression can rarely occur and has been documented through sequential photographs and histologic studies [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p>
         The rarity of such an event is supported by the observation that atypical nevi are far more common than melanoma and that more than one-half of the melanomas that occur in patients with atypical nevi develop de novo and not from a precursor atypical nevus [
         <a href="#rid27">
          27
         </a>
         ]. This is also true in patients with multiple atypical nevi. Moreover, studies of nevus-associated melanomas (ie, melanomas that show nevus remnants on histopathology) indicate that they are associated with common nevi or atypical nevi with similar frequency [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H237624">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of atypical nevus is usually clinical, based upon the finding of a predominantly macular, pigmented lesion that is larger than common melanocytic nevi (&gt;5 mm), with an irregular shape, ill-defined border, and variable color with areas of pink, tan, brown, or dark brown  (
         <a class="graphic graphic_picture graphicRef83351 graphicRef80725 graphicRef70320" href="/z/d/graphic/83351.html" rel="external">
          picture 1A-C
         </a>
         ). Other colors, such as blue, red, or white, are not usually seen in atypical nevi, and their presence increases the probability that the lesion is a melanoma.
        </p>
        <p>
         Dermoscopy is not necessary to establish the diagnosis of an atypical nevus when the clinical characteristics are well defined, but for many lesions, dermoscopy can be helpful in clarifying the benign nature of the lesion and distinguishing it from a melanoma, as these nevi share some of the ABCDE (asymmetry, border irregularities, color variegation, diameter ≥6 mm, evolution) clinical features of early melanoma. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Dermoscopic features'
         </a>
         above.)
        </p>
        <p>
         Biopsy is generally not indicated to confirm the diagnosis of an atypical nevus. However, excisional biopsy and histologic confirmation are required for lesions that are clinically and/or dermoscopically suspicious for melanoma. (See
         <a class="local">
          'Excisional/complete biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H55979238">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical nevi should be differentiated from benign and malignant, melanocytic or keratinocytic lesions, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Melanoma
         </strong>
         – Atypical nevi share some of the clinical features of melanoma, such as asymmetry, irregular borders, multiple colors, and diameter &gt;5 mm  (
         <a class="graphic graphic_picture graphicRef83351" href="/z/d/graphic/83351.html" rel="external">
          picture 1A
         </a>
         ). Distinguishing atypical nevi from superficial spreading melanoma  (
         <a class="graphic graphic_picture graphicRef71893 graphicRef82173 graphicRef61158 graphicRef74278" href="/z/d/graphic/71893.html" rel="external">
          picture 15A-D
         </a>
         ) is clearly a major difficulty in examining a patient with multiple atypical nevi  (
         <a class="graphic graphic_table graphicRef83534" href="/z/d/graphic/83534.html" rel="external">
          table 3
         </a>
         ). Since the clinical features of atypical nevi are in continuum with those of in situ melanoma, the clinician must have a sufficiently low threshold for excision to avoid missing a melanoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical findings that raise the suspicion of melanoma include (see
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shades of blue-gray, red, or white color, which are unusual in atypical nevi
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A lesion that is clinically or dermoscopically different from the predominant nevus pattern in an individual patient (the "ugly duckling" sign)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A history of rapid change (in size, color, or shape) in a pre-existing nevus over months
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A newly developed pigmented lesion in an individual older than 40 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On dermoscopy, melanoma usually deviates from the benign nevus patterns and manifests specific melanoma features. (See
         <a class="medical medical_review" href="/z/d/html/16551.html" rel="external">
          "Dermoscopy of pigmented lesions of the palms and soles", section on 'Melanoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions", section on 'Criteria for melanoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Any lesions with clinical or dermoscopic features that are suspicious of melanoma should be excised and sent for histologic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common acquired nevi
         </strong>
         – Common nevi tend to be ≤5 mm in diameter and symmetric, with a homogeneous surface, even pigmentation, round or oval shape, and a well-demarcated border  (
         <a class="graphic graphic_table graphicRef83534" href="/z/d/graphic/83534.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef81931 graphicRef57022" href="/z/d/graphic/81931.html" rel="external">
          picture 16A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">
          "Acquired melanocytic nevi (moles)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small congenital nevi
         </strong>
         – Small (&lt;1.5 cm) congenital nevi  (
         <a class="graphic graphic_picture graphicRef83920 graphicRef74734" href="/z/d/graphic/83920.html" rel="external">
          picture 17A-B
         </a>
         ) are present since birth or the first few months of life. They typically have a regular, sharply demarcated border; tan to black color; and a smooth, pebbly, or verrucous surface  (
         <a class="graphic graphic_table graphicRef83534" href="/z/d/graphic/83534.html" rel="external">
          table 3
         </a>
         ). However, some congenital nevi may have irregular and poorly demarcated borders and very dark or discontinuous pigmentation. These atypical lesions require biopsy and histologic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">
          "Congenital melanocytic nevi", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pigmented basal cell carcinoma
         </strong>
         – Pigmented basal cell carcinomas may clinically mimic an atypical melanocytic lesion  (
         <a class="graphic graphic_picture graphicRef83549" href="/z/d/graphic/83549.html" rel="external">
          picture 18
         </a>
         ). They are more often nodular and may have irregular pigmentation ranging from dark brown to black. Although dermoscopy may be helpful in differentiating pigmented basal cell carcinomas from atypical nevi or melanoma, biopsy and histologic examination are necessary for definitive diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions", section on 'Criteria for basal cell carcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seborrheic keratosis
         </strong>
         – Seborrheic keratoses typically have uniform color ranging from pink to dark brown or black, well-circumscribed borders, a dull surface, and a "stuck on" appearance  (
         <a class="graphic graphic_picture graphicRef83550 graphicRef58923 graphicRef64738" href="/z/d/graphic/83550.html" rel="external">
          picture 19A-C
         </a>
         ). Dermoscopic examination is useful in differentiating seborrheic keratoses from atypical nevi. (See
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14454977">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with atypical nevi are at increased risk of developing melanoma, although the vast majority of atypical nevi have a benign course and do not require surgical removal. Risk assessment, prevention, and early detection of melanoma are key aspects of management in these patients, which may involve:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessing the patient's personal and family history of melanoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total body skin examination
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of diagnostic aids, such as dermoscopy and total body photography
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excision and histologic examination of suspicious lesions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Education on skin self-examination and sun protection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening of family members
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic counseling and testing if appropriate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lifelong follow-up
        </p>
        <p>
        </p>
        <p>
         Routine ophthalmologic examination for ocular nevi/melanoma may be indicated in patients with atypical nevi or familial atypical mole melanoma (FAMM) syndrome [
         <a href="#rid68">
          68-70
         </a>
         ]. (See
         <a class="local">
          'Ophthalmologic examination'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H962027">
         <span class="h2">
          Assessment of patient and lesion history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with atypical nevi should be questioned about:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of atypical nevi and/or melanoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal history of melanoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changes or symptoms related to their nevi
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sun exposure habits
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14454984">
         <span class="h2">
          Full-body skin examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with atypical nevi, regular skin examination beginning around puberty provides an opportunity for education regarding sun avoidance, the importance of skin self-examinations, and the early warning signs of melanoma.
        </p>
        <p>
         Skin examination of patients with atypical nevi should include the scalp, buttocks, groin, palms, and soles [
         <a href="#rid71">
          71
         </a>
         ]. Skin examination requires a source of bright light and, ideally, a magnifying lens.
        </p>
        <p>
         The total number of nevi should be approximated. Nevi should be examined for the ABCDE (asymmetry, border irregularities, color variegation, diameter ≥6 mm, evolution) features of melanoma and for the "ugly duckling" sign. (See
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis", section on 'ABCDE criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis", section on 'The 'ugly duckling' sign'
         </a>
         .)
        </p>
        <p>
         Any nevus that is remarkably different from the predominant nevus pattern ("ugly duckling" nevus) should undergo a closer examination (dermoscopy or, if available, reflectance confocal microscopy). Any lesions for which malignancy cannot be reliably excluded should be histologically examined.
        </p>
        <p class="headingAnchor" id="H14454991">
         <span class="h2">
          Total body photography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical identification of new or changed lesions in patients with numerous nevi can be challenging  (
         <a class="graphic graphic_picture graphicRef83737" href="/z/d/graphic/83737.html" rel="external">
          picture 20
         </a>
         ). Sequential total body photography using a baseline total body photography for comparison on each follow-up examination may facilitate the detection of new lesions or changes in pre-existing nevi.
        </p>
        <p>
         The impact of total body photography on early diagnosis of melanoma and survival in high-risk patients has not been evaluated in randomized trials or large, observational studies. However, several retrospective studies provide evidence that this surveillance technique may be helpful in detecting early melanoma in patients with multiple atypical nevi and decreasing unnecessary biopsies [
         <a href="#rid54">
          54,55,72-79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14454998">
         <span class="h2">
          Dermoscopic examination and short-term dermoscopic monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermoscopy should be used by trained physicians in the evaluation of patients with atypical nevi. In two meta-analyses, dermoscopy has been shown to improve the sensitivity and specificity of melanoma diagnosis for clinicians with adequate training [
         <a href="#rid80">
          80,81
         </a>
         ]. Several studies support its usefulness, in conjunction with total body photography and clinical examination, in the early diagnosis of melanoma in patients with atypical nevi [
         <a href="#rid74">
          74,76,82-85
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lesion evaluation
         </strong>
         – Lesions are evaluated by using one of the several algorithms designed to differentiate benign from suspicious or malignant lesions, including the Menzies method, the ABCD (asymmetry, border sharpness, colors, differential dermoscopic structure) rule of dermoscopy, the seven-point checklist, or pattern analysis. (See
         <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">
          "Dermoscopic evaluation of skin lesions", section on 'Other algorithms and methods'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Atypical nevi with dermoscopic features that deviate from the benign nevus patterns and are suspicious of melanoma should be biopsied [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short-term dermoscopic monitoring
         </strong>
         – Short-term monitoring of suspicious lesions by sequential digital dermoscopy may be useful in identifying early melanomas, especially featureless melanomas, on the basis of changes detected in sequential images [
         <a href="#rid86">
          86-88
         </a>
         ]. A reasonable interval for short-term mole monitoring is three months [
         <a href="#rid86">
          86,89,90
         </a>
         ]. Approximately 10 to 20 percent of changing lesions on short-term monitoring have been shown to be melanoma on biopsy [
         <a href="#rid86">
          86,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H647927">
         <span class="h2">
          Excisional/complete biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic excision of atypical nevi is
         <strong>
          not
         </strong>
         recommended because the risk of melanoma developing in an individual atypical nevus is extremely low and the majority of melanomas arise de novo [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="local">
          'Are atypical nevi melanoma precursors?'
         </a>
         above.)
        </p>
        <p>
         However, new, changing, or symptomatic lesions that are suspicious of melanoma on clinical and/or dermoscopic examination should be excised and sent for histologic examination.
        </p>
        <p>
         For clinicians who are proficient in the use of dermoscopy, dermoscopic examination may be helpful in deciding whether an atypical nevus should be biopsied or monitored. (See
         <a class="local">
          'Dermoscopic features'
         </a>
         above.)
        </p>
        <p>
         Regardless of the surgical technique employed (eg, scalpel excision, punch biopsy, or shave/saucerization removal), the lesion should be excised with a 2 to 3 mm margin of normal skin beyond the area of pigmentation [
         <a href="#rid44">
          44,45,92,93
         </a>
         ]. Partial or superficial/tangential shave biopsies are discouraged to avoid sampling error and reduce the risk of nevus recurrence [
         <a href="#rid94">
          94
         </a>
         ]. Persistent or recurrent pigmentation at the biopsy site can be difficult to differentiate from melanoma clinically and histologically [
         <a href="#rid94">
          94-96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis", section on 'Biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H647934">
         <span class="h2">
          Re-excision
         </span>
         <span class="headingEndMark">
          —
         </span>
         Re-excision of atypical nevi with positive margins on histologic examination is a common practice among dermatologists, although there are no universally accepted guidelines [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p>
         A consensus statement from members of the Pigmented Lesion Subcommittee of the Melanoma Prevention Working Group recommended that mildly dysplastic nevi and moderately dysplastic nevi biopsied with clear histologic margins following initial excisional/complete biopsy
         <strong>
          do not need
         </strong>
         re-excision, and mildly dysplastic nevi with positive histologic margins following biopsy without evidence of clinically residual pigmentation may be safely observed [
         <a href="#rid99">
          99
         </a>
         ]. Observation was also deemed a reasonable option for moderately dysplastic nevi with positive histologic margins and no clinically apparent residual pigmentation.
        </p>
        <p>
         However, patients with atypical nevi showing severe histologic atypia and positive biopsy margins may benefit from re-excision to confirm the diagnosis and exclude melanoma. Conservative re-excision with 2 to 3 mm margins may be sufficient for atypical nevi with severe histologic atypia with or without residual nevus in the initial excision specimen [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Observational studies suggest that the risk of melanoma developing at a biopsy site with positive margins is very low and not clearly reduced by re-excision.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 systematic review including 12 observational studies examined the clinical outcome of atypical nevi that were re-excised (n = 1138) or observed (n = 1535) [
         <a href="#rid101">
          101
         </a>
         ]. The follow-up time was specified in nine studies and ranged from 2 weeks to 30 years. Of 2673 atypical nevi of all grades of histologic atypia, 11 (0.4 percent) developed melanoma at the site of the biopsy, of which five (0.44 percent) were in the re-excision group and six (0.39 percent) were in the observation group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, the six melanomas that occurred in the observation group were reported in a single study of 474 atypical nevi with positive margins followed for an average of 5.5 years [
         <a href="#rid102">
          102
         </a>
         ]. Five of six melanomas developed in nevi that had undergone only a partial biopsy and had grossly positive margins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the results of this systematic review should be viewed with caution, given the low methodologic quality and the high risk of bias of the included studies, they indicate that the risk of melanoma developing at the site of a biopsied atypical nevus is generally low and possibly not mitigated by re-excision.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subsequent multicenter study including 438 patients with 467 moderately dysplastic nevi with positive histologic margins, none of the patients developed a melanoma at the biopsy site after a mean follow-up period of 6.9 years [
         <a href="#rid103">
          103
         </a>
         ]. However, 100 patients (23 percent) developed a melanoma at a separate site, highlighting the importance of ongoing clinical surveillance in patients with atypical nevi. On multivariate analysis, factors independently associated with the development of melanoma were a previous history of melanoma and history of one or more prior biopsied dysplastic nevi (odds ratio [OR] 11.7, 95% CI 5.7-24.1 and OR 2.6, 95% CI 1.2-5.3, respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H417714">
         <span class="h2">
          Patient education
         </span>
         <span class="headingEndMark">
          —
         </span>
         Education on the importance of skin self-examination and sun protection is an integral part of the management of patients with atypical nevi.
        </p>
        <p class="headingAnchor" id="H14455012">
         <span class="h3">
          Skin self-examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular skin self-examination is recommended for several reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melanomas are first detected by patients in approximately one-half of cases [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Self-examination, particularly when combined with regular clinician examination, may be associated with early diagnosis of thinner melanoma [
         <a href="#rid105">
          105,106
         </a>
         ]. In a multicenter study that included 800 patients diagnosed with melanoma, the habit of performing skin self-examination was associated with a lower risk of having a melanoma &gt;1 mm in thickness (OR 0.65, 95% CI 0.45-0.93) [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patient information on how to perform self-examination and recognize early signs of melanoma is available from several organizations, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fpublic%2Fdiseases%2Fskin-cancer%2Ffind&amp;token=%2BZRpnl%2BXhyeV0IxFnyD0gqdHWkS9Mlhz7I%2Fjd2Ta%2F6RXhzK6etO%2BhPmGCRXaYXuFcak78b0BKx2vZzbmhvRufQ%3D%3D&amp;TOPIC_ID=13519" target="_blank">
          The American Academy of Dermatology
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.skincancer.org%2Fearly-detection%2F&amp;token=FWNID0ZRoEvvwjKjY4KwHR%2FIvNY3kYF6JqVz27ZRSvGWdwcbLKXYHqZiiXZrdqZLE6AxRrQqkNG8EfrDLkUyxw%3D%3D&amp;TOPIC_ID=13519" target="_blank">
          The Skin Cancer Foundation
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.org%2Fcancer%2Ftypes%2Fmelanoma-skin-cancer.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLCs7CD%2BikVC9DemCfI%2BKTG7QgfJe03phTikuHEQAyM4vhOlBOPsQXlqmHz4sTuHayA%3D%3D&amp;TOPIC_ID=13519" target="_blank">
          The American Cancer Society
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgenomel.org%2Finfo-for-patients%2F&amp;token=9tNWJ%2B3BYy5X4qBW0c8I5ROhKhgsFeZa7Nns%2For8rnm5%2FieWiRKzkNmcB8zvpSto&amp;TOPIC_ID=13519" target="_blank">
          The Melanoma Genetics Consortium
         </a>
         (GenoMEL)
        </p>
        <p>
        </p>
        <p>
         Educating patients on the identification of clinical outliers ("ugly ducklings") may also be beneficial. In an interobserver agreement study involving dermatologists, nurses, and nonclinicians, the sensitivity and specificity of the ugly duckling sign in the detection of melanoma were 0.85 and 0.83, respectively, among nonclinicians [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14455026">
         <span class="h3">
          Sun protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sun and tanning bed avoidance and use of protective clothing, sunglasses, and broad-spectrum sunscreens are recommended for individuals with atypical nevi  (
         <a class="graphic graphic_table graphicRef83780" href="/z/d/graphic/83780.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid107">
          107-112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">
          "Selection of sunscreen and sun-protective measures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4842.html" rel="external">
          "Primary prevention of melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14455033">
         <span class="h2">
          Genetic counseling and testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic counseling is not indicated for patients with atypical nevi in the absence of a family history suggesting FAMM syndrome [
         <a href="#rid113">
          113,114
         </a>
         ]. (See
         <a class="local">
          'FAMM syndrome'
         </a>
         above.)
        </p>
        <p>
         GenoMEL recommends that deoxyribonucleic acid (DNA) testing for mutations in melanoma susceptibility genes be performed only rarely outside of defined research programs [
         <a href="#rid113">
          113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma", section on 'CDKN2A gene'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H417634">
         <span class="h2">
          Ophthalmologic examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine ophthalmologic examination is indicated in patients with many atypical nevi because they have an increased prevalence of ocular melanocytic nevi and may be at increased risk of developing ocular melanoma [
         <a href="#rid68">
          68-70,115-118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7617.html" rel="external">
          "Initial management of uveal and conjunctival melanomas", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H238019">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal frequency of skin examinations in individuals with atypical nevi has not been determined. Examinations are generally performed at intervals of 3 to 12 months based upon phenotypic characteristics, personal or family history of melanoma, and competence in self-examination [
         <a href="#rid119">
          119,120
         </a>
         ]. High-risk patients should ideally be followed in a pigmented lesion clinic or by a clinician with experience in the diagnosis of melanoma.
        </p>
        <p class="headingAnchor" id="H238034">
         <span class="h2">
          Patients with few common nevi and one or few atypical nevi
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <strong>
          annual
         </strong>
         total body skin examination for patients with few common nevi and one or few atypical nevi without a personal and/or family history of melanoma. The frequency of skin examination may be higher for patients who also have a personal and/or family history of melanoma or lower if the patient is proficient at skin self-examination. (See
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma", section on 'Surveillance in melanoma-prone kindreds'
         </a>
         .)
        </p>
        <p>
         Baseline digital photographs and/or dermoscopic images of single atypical nevi may be useful for comparison at follow-up visits. (See
         <a class="local">
          'Total body photography'
         </a>
         above and
         <a class="local">
          'Dermoscopic examination and short-term dermoscopic monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H416502">
         <span class="h2">
          Patients with numerous common and atypical nevi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with numerous common and atypical nevi have a high risk of developing melanoma. The risk is greatest for patients who also have a personal and/or family history of melanoma and for patients with familial atypical mole melanoma (FAMM) syndrome. These high-risk patients should be ideally followed in a pigmented lesion clinic or by a clinician with experience in the diagnosis of melanoma.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with many atypical nevi and without a personal or family history of melanoma, we suggest total body skin examinations at 6- to 12-month intervals, or earlier if the patient notices any changes in a lesion's size, shape, or color. Follow-up may be annual for patients who are judged competent at self-surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who have a personal history of melanoma, we suggest follow-up visits at 3- to 12-month intervals, depending on melanoma stage and time elapsed since melanoma diagnosis, or earlier if the patient notices any changes in a lesion's size, shape, or color.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In FAMM kindreds, screening for melanoma should begin around puberty with a baseline total body skin examination. Follow-up examinations are scheduled every six months until the nevus pattern is stable and the patient is judged competent at self-surveillance and then every 3 to 12 months depending on the rate of melanoma development [
         <a href="#rid30">
          30,113,121,122
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         High-risk patients should be advised to perform regular skin self-examinations. Ideally, a family member, caregiver, or partner should be involved in the examination of areas not accessible to self-examination. (See
         <a class="local">
          'Skin self-examination'
         </a>
         above.)
        </p>
        <p>
         Total body photography and digital dermoscopy may be particularly useful in the management of patients with high mole counts [
         <a href="#rid54">
          54,55,72-75
         </a>
         ]. (See
         <a class="local">
          'Total body photography'
         </a>
         above and
         <a class="local">
          'Dermoscopic examination and short-term dermoscopic monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3655238055">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121558.html" rel="external">
          "Society guideline links: Atypical nevi"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14455047">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Atypical (dysplastic) nevi are benign acquired melanocytic neoplasms that share some of the clinical features of melanoma, such as large diameter, irregular borders, and multiple colors  (
         <a class="graphic graphic_picture graphicRef83351" href="/z/d/graphic/83351.html" rel="external">
          picture 1A
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Terminology and historical background'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical nevi and risk of melanoma
         </strong>
         – Individuals with atypical nevi have a 3- to 20-fold higher risk of developing a melanoma than individuals without atypical nevi. The risk of melanoma increases in a dose-response fashion with the number of atypical nevi and is greatest in individuals with atypical nevi and a personal or family history of melanoma. The role of atypical nevi as precursors of melanoma is controversial. Although they share some of the clinical, pathologic, and genetic features of melanoma, most atypical nevi will never progress to melanoma. (See
         <a class="local">
          'Clinical significance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Atypical nevi are most often seen on the trunk and extremities, although they can develop anywhere on the body, including the scalp, breasts, buttocks, and genitalia  (
         <a class="graphic graphic_picture graphicRef78891 graphicRef83351" href="/z/d/graphic/78891.html" rel="external">
          picture 1A, 2A
         </a>
         ). Clinical features include diameter &gt;5 mm  (
         <a class="graphic graphic_picture graphicRef80725" href="/z/d/graphic/80725.html" rel="external">
          picture 1B
         </a>
         ); prominent macular component  (
         <a class="graphic graphic_picture graphicRef83466" href="/z/d/graphic/83466.html" rel="external">
          picture 3
         </a>
         ); irregular, ill-defined borders  (
         <a class="graphic graphic_picture graphicRef70320" href="/z/d/graphic/70320.html" rel="external">
          picture 1C
         </a>
         ); and variegated color  (
         <a class="graphic graphic_picture graphicRef83351" href="/z/d/graphic/83351.html" rel="external">
          picture 1A
         </a>
         ). (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histopathology
         </strong>
         – Histologically, atypical nevi are characterized by architectural disorder, cytologic atypia, and host response features. (See
         <a class="local">
          'Histologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of atypical nevus is clinical and based upon the finding of a predominantly macular, pigmented lesion that is &gt;5 mm with an irregular shape, ill-defined border, and variable color  (
         <a class="graphic graphic_picture graphicRef83351 graphicRef80725 graphicRef70320" href="/z/d/graphic/83351.html" rel="external">
          picture 1A-C
         </a>
         ). Biopsy is not indicated to confirm the presence of histologic dysplasia in the absence of features that suggest melanoma. However, lesions that are suspicious for melanoma on clinical and/or dermoscopic examination should be completely removed and sent for histologic examination for diagnosis confirmation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of patients with multiple atypical nevi may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assessment of history (see
         <a class="local">
          'Assessment of patient and lesion history'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Total body skin examination (see
         <a class="local">
          'Full-body skin examination'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of diagnostic aids such as dermoscopy and total body photography (see
         <a class="local">
          'Total body photography'
         </a>
         above and
         <a class="local">
          'Dermoscopic examination and short-term dermoscopic monitoring'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Excision with 2 to 3 mm margins and histologic examination of suspicious lesions for melanoma (see
         <a class="local">
          'Excisional/complete biopsy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis", section on 'Biopsy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Education on skin self-examination and sun protection (see
         <a class="local">
          'Skin self-examination'
         </a>
         above and
         <a class="local">
          'Sun protection'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic counseling and testing (see
         <a class="local">
          'Genetic counseling and testing'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lifelong follow-up (see
         <a class="local">
          'Follow-up'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of skin examination
         </strong>
         – We base our frequency of skin examination on the number of atypical nevi and other risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          One or few atypical nevi
         </strong>
         – For patients with few common nevi and one or a few atypical nevi without a personal and/or family history of melanoma, we suggest annual total body skin examinations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The frequency of skin examination may be higher (every 3 to 12 months) for patients who have a personal and/or family history of melanoma. (See
         <a class="local">
          'Patients with few common nevi and one or few atypical nevi'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Many atypical nevi
         </strong>
         – For patients with many atypical nevi and without a personal or family history of melanoma, we suggest total body skin examinations at 6- to 12-month intervals, or earlier if the patient notices any changes in a lesion's size, shape, or color.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with many atypical nevi who also have a personal history of melanoma, we suggest follow-up visits at 3- to 12-month intervals, depending on melanoma stage and time elapsed since melanoma diagnosis, or earlier if the patient notices any changes in a lesion's size, shape, or color.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In familial atypical mole melanoma (FAMM) syndrome kindreds, screening for melanoma should begin at the age of 10. (See
         <a class="local">
          'Patients with numerous common and atypical nevi'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rosendahl CO, Grant-Kels JM, Que SK. Dysplastic nevus: Fact and fiction. J Am Acad Dermatol 2015; 73:507.
          </a>
         </li>
         <li class="breakAll">
          Diagnosis and Treatment of Early Melanoma. NIH Consens Statement Online 1992; 10:1. http://consensus.nih.gov/1992/1992Melanoma088html.htm (Accessed on April 23, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro M, Chren MM, Levy RM, et al. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol 2004; 31:523.
          </a>
         </li>
         <li class="breakAll">
          Elder DE, Barnhill RL, Bastian BC, et al. Dysplastic naevus. In: WHO Classification of Skin Tumours, 4th ed, Elder DE, Massi D, Scolyer RA, Willemze R (Eds), IARC Press, 2018. Vol 11.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978; 239:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene MH, Clark WH Jr, Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980; 2:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. J Am Acad Dermatol 1990; 22:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piepkorn M, Meyer LJ, Goldgar D, et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989; 20:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schäfer T, Merkl J, Klemm E, et al. The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000. J Invest Dermatol 2006; 126:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augustsson A, Stierner U, Suurküla M, Rosdahl I. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991; 124:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hübner J, Waldmann A, Eisemann N, et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. Eur J Cancer Prev 2018; 27:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern AC, Guerry D 4th, Elder DE, et al. Natural history of dysplastic nevi. J Am Acad Dermatol 1993; 29:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang YM, Newton-Bishop JA, Bishop DT, et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009; 124:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abadir MC, Marghoob AA, Slade J, et al. Case-control study of melanocytic nevi on the buttocks in atypical mole syndrome: role of solar radiation in the pathogenesis of atypical moles. J Am Acad Dermatol 1995; 33:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopf AW, Lindsay AC, Rogers GS, et al. Relationship of nevocytic nevi to sun exposure in dysplastic nevus syndrome. J Am Acad Dermatol 1985; 12:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augustsson A, Stierner U, Rosdahl I, Suurküla M. Melanocytic naevi in sun-exposed and protected skin in melanoma patients and controls. Acta Derm Venereol 1991; 71:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 2007; 29:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sini MC, Manca A, Cossu A, et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 2008; 158:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uribe P, Wistuba II, González S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003; 25:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melamed RD, Aydin IT, Rajan GS, et al. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma. J Invest Dermatol 2017; 137:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015; 373:1926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celebi JT, Ward KM, Wanner M, et al. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol 2005; 30:68.
          </a>
         </li>
         <li class="breakAll">
          Eckerle Mize D, Bishop M, Resse E, Sluzevich J. Familial atypical multiple mole melanoma syndrome. In: Cancer Syndromes, Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M. (Eds), National Center for Biotechnology Information (US), 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008; 7:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annessi G, Cattaruzza MS, Abeni D, et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. J Am Acad Dermatol 2001; 45:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 357:j2813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993; 29A:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duncan LM, Berwick M, Bruijn JA, et al. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993; 100:318S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994; 30:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydin Ulgen O, Yıldız P, Acar HC, Demirkesen C. Analysis of interobserver reproducibility in grading dysplastic nevi: Results of the application of the 2018 World Health Organization grading criteria. J Cutan Pathol 2022; 49:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003; 16:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta M, Berk DR, Gray C, et al. Morphologic features and natural history of scalp nevi in children. Arch Dermatol 2010; 146:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguilera P, Puig S, Guilabert A, et al. Prevalence study of nevi in children from Barcelona. Dermoscopy, constitutional and environmental factors. Dermatology 2009; 218:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Synnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Frequency and distribution pattern of melanocytic naevi in Swedish 8-9-year-old children. Acta Derm Venereol 2004; 84:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crutcher WA, Cohen PJ. Dysplastic nevi and malignant melanoma. Am Fam Physician 1990; 42:372.
          </a>
         </li>
         <li class="breakAll">
          Robinson JK. Surgery of the Skin: Procedural Dermatology - Expert Consult, 2nd ed, Mosby, 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolognia JL, Lin A, Shapiro PE. The significance of eccentric foci of hyperpigmentation ('small dark dots') within melanocytic nevi. Analysis of 59 cases. Arch Dermatol 1994; 130:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scope A, Burroni M, Agero AL, et al. Predominant dermoscopic patterns observed among nevi. J Cutan Med Surg 2006; 10:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh KY, Bolognia JL. Signature nevi. J Am Acad Dermatol 2009; 60:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scope A, Dusza SW, Halpern AC, et al. The "ugly duckling" sign: agreement between observers. Arch Dermatol 2008; 144:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol 2001; 137:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2002; 20:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991; 17:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern AC, Guerry D 4th, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100:346S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbe C, Krüger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989; 28:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988; 17:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augustsson A, Stierner U, Rosdahl I, Suurküla M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991; 71:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang S, Barnhill RL, Mihm MC Jr, et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiedemeyer K, Hartschuh W, Brenn T. Dysplastic Nevi: Morphology and Molecular and the Controversies In-between. Surg Pathol Clin 2021; 14:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng H, Jorapur A, Shain AH, et al. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Cancer Cell 2018; 34:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker MA, Fraser MC, Goldstein AM, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 2002; 94:3192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bevona C, Goggins W, Quinn T, et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pampena R, Kyrgidis A, Lallas A, et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayman T, Bostan C, Logan P, Burnier MN Jr. Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses. Curr Eye Res 2017; 42:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richtig E, Langmann G, Müllner K, Smolle J. Ocular melanoma: epidemiology, clinical presentation and relationship with dysplastic nevi. Ophthalmologica 2004; 218:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammer H, Tóth-Molnár E, Oláh J, Dobozy A. [Connection between uveal melanoma and dysplastic naevus syndrome]. Magy Onkol 2005; 49:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986; 14:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997; 167:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004; 150:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SQ, Kopf AW, Koenig K, et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol 2004; 50:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risser J, Pressley Z, Veledar E, et al. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol 2007; 57:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong A, Strazzulla L, March J, et al. Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol 2016; 75:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodson AG, Florell SR, Hyde M, et al. Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg 2010; 36:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salerni G, Carrera C, Lovatto L, et al. Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. J Am Acad Dermatol 2012; 67:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol 2006; 126:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 2000; 43:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salerni G, Carrera C, Lovatto L, et al. Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012; 67:e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscarella E, Tion I, Zalaudek I, et al. Both short-term and long-term dermoscopy monitoring is useful in detecting melanoma in patients with multiple atypical nevi. J Eur Acad Dermatol Venereol 2017; 31:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol 2008; 144:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuller SR, Bowen GM, Tanner B, et al. Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg 2007; 33:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus SL, Haenssle HA. Early detection of cutaneous melanoma by sequential digital dermatoscopy (SDD). J Dtsch Dermatol Ges 2013; 11:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argenziano G, Kittler H, Ferrara G, et al. Slow-growing melanoma: a dermoscopy follow-up study. Br J Dermatol 2010; 162:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haenssle HA, Korpas B, Hansen-Hagge C, et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol 2010; 146:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menzies SW, Gutenev A, Avramidis M, et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001; 137:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol 1993; 15:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terushkin V, Ng E, Stein JA, et al. A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. J Am Acad Dermatol 2017; 77:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park HK, Leonard DD, Arrington JH 3rd, Lund HZ. Recurrent melanocytic nevi: clinical and histologic review of 175 cases. J Am Acad Dermatol 1987; 17:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornberg R, Ackerman AB. Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. Arch Dermatol 1975; 111:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommer LL, Barcia SM, Clarke LE, Helm KF. Persistent melanocytic nevi: a review and analysis of 205 cases. J Cutan Pathol 2011; 38:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol 2002; 46:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffy KL, Mann DJ, Petronic-Rosic V, Shea CR. Clinical decision making based on histopathologic grading and margin status of dysplastic nevi. Arch Dermatol 2012; 148:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CC, Swetter SM, Curiel-Lewandrowski C, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol 2015; 151:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soleymani T, Swetter SM, Hollmig ST, Aasi SZ. Adequacy of conservative 2- to 3-mm surgical margins for complete excision of biopsy-proven severely dysplastic nevi: Retrospective case series at a tertiary academic institution. J Am Acad Dermatol 2020; 83:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuong KT, Walker J, Powell HB, et al. Surgical re-excision vs. observation for histologically dysplastic naevi: a systematic review of associated clinical outcomes. Br J Dermatol 2018; 179:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming NH, Egbert BM, Kim J, Swetter SM. Reexamining the Threshold for Reexcision of Histologically Transected Dysplastic Nevi. JAMA Dermatol 2016; 152:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CC, Berry EG, Marchetti MA, et al. Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. JAMA Dermatol 2018; 154:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher NM, Schaffer JV, Berwick M, Bolognia JL. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005; 53:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial. Am J Prev Med 2007; 32:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000; 283:2955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer 2011; 128:2425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 19:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veierød MB, Adami HO, Lund E, et al. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010; 19:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61:677.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toth-Molnar E, Olah J, Dobozy A, Hammer H. Ocular pigmented findings in patients with dysplastic naevus syndrome. Melanoma Res 2004; 14:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology 2009; 116:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Sains RS. Ocular findings in patients with dysplastic nevus syndrome. An update. Dermatol Clin 1991; 9:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammer H, Oláh J, Tóth-Molnár E. Dysplastic nevi are a risk factor for uveal melanoma. Eur J Ophthalmol 1996; 6:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmann RR, Rigel DS. Management of dysplastic nevi: A 14-year follow-up survey assessing practice trends among US dermatologists. J Am Acad Dermatol 2015; 73:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puig S, Malvehy J. Monitoring patients with multiple nevi. Dermatol Clin 2013; 31:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czajkowski R, Placek W, Drewa G, et al. FAMMM syndrome: pathogenesis and management. Dermatol Surg 2004; 30:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 2016; 74:395.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13519 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26037217" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dysplastic nevus: Fact and fiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26037217" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dysplastic nevus: Fact and fiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15268706" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15268706" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/646394" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/739524" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Familial atypical multiple mole-melanoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/621895" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7427881" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6107646" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2298947" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Atypical mole syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2918113" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9145715" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645597" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2003997" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prevalence of common and dysplastic naevi in a Swedish population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28692584" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315078" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Natural history of dysplastic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18792098" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7601943" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Case-control study of melanocytic nevi on the buttocks in atypical mole syndrome: role of solar radiation in the pathogenesis of atypical moles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3989027" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Relationship of nevocytic nevi to sun exposure in dysplastic nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1685834" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Melanocytic naevi in sun-exposed and protected skin in melanoma patients and controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150307" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490270" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032947" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18028495" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501284" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27125352" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : From melanocytes to melanomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27890785" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559571" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The Genetic Evolution of Melanoma from Precursor Lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663508" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663508" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16905682" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10922411" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992582" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pancreatic cancer and the FAMMM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11423839" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28659278" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8484972" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440913" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8176008" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34758119" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Analysis of interobserver reproducibility in grading dysplastic nevi: Results of the application of the 2018 World Health Organization grading criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12920220" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Grading of atypia in nevi: correlation with melanoma risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20479298" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Morphologic features and natural history of scalp nevi in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060476" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prevalence study of nevi in children from Barcelona. Dermoscopy, constitutional and environmental factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15339070" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Frequency and distribution pattern of melanocytic naevi in Swedish 8-9-year-old children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2200246" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dysplastic nevi and malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2200246" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Dysplastic nevi and malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8053697" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The significance of eccentric foci of hyperpigmentation ('small dark dots') within melanocytic nevi. Analysis of 59 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17234115" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predominant dermoscopic patterns observed among nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19231649" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Signature nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9449921" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209169" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The "ugly duckling" sign: agreement between observers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11735707" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dermoscopic classification of atypical melanocytic nevi (Clark nevi).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12074861" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Dermoscopic classification of Clark's nevi (atypical melanocytic nevi).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369719" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991880" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440922" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A cohort study of melanoma in patients with dysplastic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2583889" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Markers and relative risk in a German population for developing malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3405984" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1685835" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15617989" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8053717" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Melanoma risk in individuals with clinically atypical nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20086181" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34023110" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dysplastic Nevi: Morphology and Molecular and the Controversies In-between.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29990501" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12115352" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14676081" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cutaneous melanomas associated with nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2095738" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28864306" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A meta-analysis of nevus-associated melanoma: Prevalence and practical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28494168" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15004500" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Ocular melanoma: epidemiology, clinical presentation and relationship with dysplastic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902328" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : [Connection between uveal melanoma and dysplastic naevus syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3711396" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Importance of complete cutaneous examination for the detection of malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9293264" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15099367" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Melanomas detected with the aid of total cutaneous photography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699359" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17624623" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16103329" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26947450" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Reduction in nevus biopsies in patients monitored by total body photography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20653722" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22521205" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18616769" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11902502" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Diagnostic accuracy of dermoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16514414" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10954658" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21683472" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27422807" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Both short-term and long-term dermoscopy monitoring is useful in detecting melanoma in patients with multiple atypical nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18427044" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17903152" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23452303" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Early detection of cutaneous melanoma by sequential digital dermatoscopy (SDD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19785607" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Slow-growing melanoma: a dermoscopy follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231495" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11735708" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8434730" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28982585" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3624565" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Recurrent melanocytic nevi: clinical and histologic review of 175 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1200664" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21362017" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Persistent melanocytic nevi: a review and analysis of 205 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12004306" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22351835" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Clinical decision making based on histopathologic grading and margin status of dysplastic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25409291" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31972255" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Adequacy of conservative 2- to 3-mm surgical margins for complete excision of biopsy-proven severely dysplastic nevi: Retrospective case series at a tertiary academic institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29570779" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Surgical re-excision vs. observation for histologically dysplastic naevi: a systematic review of associated clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27542070" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Reexamining the Threshold for Reexcision of Histologically Transected Dysplastic Nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30304348" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112344" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17533068" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12756097" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21135266" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Reduced melanoma after regular sunscreen use: randomized trial follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10865273" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20669232" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17131335" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20507845" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Indoor tanning and risk of melanoma: a case-control study in a highly exposed population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056629" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506626" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19751883" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Selection criteria for genetic assessment of patients with familial melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15091193" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Ocular pigmented findings in patients with dysplastic naevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19167086" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1934647" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Ocular findings in patients with dysplastic nevus syndrome. An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8997595" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Dysplastic nevi are a risk factor for uveal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26568339" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Management of dysplastic nevi: A 14-year follow-up survey assessing practice trends among US dermatologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24075545" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Monitoring patients with multiple nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871223" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : FAMMM syndrome: pathogenesis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26892650" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
